Group 1 - The stock price of Saily Medical (603716) closed at 23.29 yuan on January 28, 2026, down 4.71%, with a turnover rate of 7.5%, trading volume of 157,600 shares, and a transaction amount of 374 million yuan [1] - On January 28, 2026, there was a net outflow of 37.966 million yuan from institutional investors and 33.4873 million yuan from retail investors, while retail investors had a net inflow of 71.4533 million yuan [1][4] - A block trade occurred on January 28, 2026, with a transaction amount of 22 million yuan [2] Group 2 - Saily Medical announced that its major shareholder, Shanghai Angze Private Fund Management Co., Ltd., reduced its holdings by a total of 1.5 million shares from December 12, 2025, to January 28, 2026, accounting for 0.7137% of the company's total share capital, during which the stock price increased by 12.4% [3] - The total reduction by Shanghai Angze Private Fund amounted to 3,091,200 shares, representing 1.47% of the total share capital, with a reduction price range of 19.64 to 22.00 yuan per share, totaling 65.226349 million yuan [3][4] - After the reduction, Shanghai Angze held 9,009,199 shares, accounting for 4.29% of the total share capital, and is no longer classified as a major shareholder [3][4]

Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

Group 1 - The core point of the article is that Shanghai Anze has completed a share reduction plan, decreasing its holdings in the company by approximately 3.09 million shares, which represents about 0.99% of the total share capital as of December 10, 2025 [1] - From December 4 to December 17, 2025, Shanghai Anze reduced its shares by approximately 2.09 million shares through centralized bidding, which is 0.99% of the total share capital [1] - On January 28, 2026, Shanghai Anze further reduced its holdings by 1 million shares through block trading, accounting for 0.48% of the total share capital as of January 20, 2026 [1] Group 2 - After the completion of the share reduction, Shanghai Anze holds approximately 9.01 million shares, which is 4.29% of the total share capital as of January 20, 2026 [1] - The share reduction plan has been fully implemented, indicating a strategic decision by Shanghai Anze regarding its investment in the company [1]

责任编辑：小浪快报 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为2200万元。该股近5个交易日累计 下跌5.21%，主力资金合计净流出1.07亿元。 1月28日，塞力医疗（维权）收跌4.71%，收盘价为23.29元，发生1笔大宗交易，合计成交量100万股， 成交金额2200万元。 第1笔成交价格为22.00元，成交100.00万股，成交金额2,200.00万元，溢价率为-5.54%，买方营业部为方 正证券股份有限公司湖北分公司，卖方营业部为财通证券股份有限公司上海分公司。 ...

| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2026-006 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 持股 5%以上股东的基本情况 减持计划实施前，上海盎泽私募基金管理有限公司-盎泽太盈六号私募证券 投资基金(以下简称"上海盎泽"）持有塞力斯医疗科技集团股份有限公司（以下 简称"公司"）12,100,399 股无限售条件流通股，占截至 2025 年 8 月 20 日（公 司总股本为 210,139,246 股)公司总股本的 5.76%。上述股份来源于公司控股股 东赛海（上海）健康科技有限公司协议转让后取得的股份。 减持计划的实施结果情况 2025 年 10 月 1 日，公司披露了《关于持股 5%以上股东减持股份计划公告》 （公告编号：2025-087），上海盎泽计划在公告披露日起 15 个交易日后的三个月 （即 2025 年 10 月 30 日至 2 ...

格隆汇1月28日丨塞力医疗（维权）(603716.SH)公布，截至2026年1月28日，上海盎泽已完成本次减持 计划，通过集中竞价交易和大宗交易的方式合计减持公司股份3,091,200股，占公司截至2026年1月20日 （总股本为210,199,126股)总股本的1.47%。本次减持完成后，上海盎泽剩余持有公司股份9,009,199股， 占公司截至2026年1月20日总股本的4.29%。 ...

南财智讯1月28日电，塞力医疗公告，公司持股5%以上股东上海盎泽私募基金管理有限公司-盎泽太盈 六号私募证券投资基金于2025年12月4日至2026年1月28日期间，通过集中竞价及大宗交易方式合计减持 公司股份3,091,200股，占公司截至2026年1月20日总股本210,199,126股的1.47%。本次减持计划已实施 完毕，减持后上海盎泽持有公司股份9,009,199股，占总股本的4.29%。 ...

格隆汇1月28日｜塞力医疗（维权）公告称，减持计划实施前，上海盎泽持有公司1210.04万股，占总股 本5.76%。2025年10月1日，上海盎泽披露减持计划，拟在2025年10月30日至2026年1月29日减持不超 420.28万股，占总股本2%。截至2026年1月28日，上海盎泽已完成减持，通过集中竞价和大宗交易合计 减持309.12万股，占截至2026年1月20日总股本的1.47%，减持总金额6522.63万元。减持后，上海盎泽 剩余持股900.92万股，占比4.29%。 ...

| 成交量(万 | 成交金额(万 | 成交价格 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | | 股) | 元) | (元) | | | | | | | 方正证券股份有限公司湖北分 | 财通证券股份有限公司上海分 | | 100.00 | 2200.00 | 22.00 | | | | | | | 公司 | 公司 | （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨 询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保 证和承诺。 塞力医疗01月28日大宗交易平台共发生1笔成交，合计成交量100.00万股，成交金额2200.00万元。成交 价格平均为22.00元，相对今日收盘价折价5.54%。 01月28日塞力医疗大宗交易一览 ...

| 交易日期 | | 券代码 成 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 奥出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | | 026-01-28 | 塞力医疗 | 603716 22 22 2200 | 100 | 态焉嫣然劈堡有限 | 髮槽里킬劈纹葫芦 | Ka | 1月28日，塞力医疗大宗交易成交100万股，成交额2200万元，占当日总成交额的5.55%，成交价22元， 较市场收盘价23.29元折价5.54%。 ...